AndhraNews.net
Home » Features » Health » Lung Cancer

Lung Cancer


About Lung Cancer

Lung cancer is the second most common cause of death among women. A recent trend show that Lung cancer becomes biggest killer of Australian women.

Reducing Lung cancer risk

A diverse diet of fruits and vegetables may decrease the risk of lung cancer - especially if you smoke.

Lung cancer market

Decision Resources, a research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013.

Recent research on Lung cancer

Victims of Lung cancer

Celebrities diagnosed with Lung Cancer

Tony Greig

Former England Cricket captain Tony Greig is diagnosed with lung cancer in October 2012. Greig will undergo a surgery to find the extent of the disease. He was initially diagnosed with bronchitis in May 2012. "I have had a few scrapes in my life and this is another one. Vivian and I are going to put the boxing gloves on and fight this like we've never fought anything before.", he said.

Tony Greig will have an operation in the third week of November 2012. He was absent in the commentary box on the first cricket test between Australia and South Africa on 9 November 2012. He is having tests which confirmed the necessity for an operation. Greig's old adversary Dennis Lillee spoke to Greig on phone which was said to have lifted the spirits of Greig.

Other information

Lung Cancer in News

Sunshine Biopharma Acquires All Remaining Worldwide Patents for Its Adva-27a Anticancer Compound
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the remaining rights, title and interest in and to all worldwide patents for the Company's Adva-27a anticancer compound

Menssana Research Breath Test Predicts Lung Cancer
NEWARK, NJ--(Marketwired - December 23, 2015) - An advanced new breath test accurately predicted lung cancer in a blinded clinical study.

Helix BioPharma Corp. Initiates Enrollment for Fifteenth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate l-DOS47
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the fifteenth (15) dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002").

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients
SAN CARLOS, CA--(Marketwired - December 17, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments

Online Disruptive Technologies Announces Approval to Perform Diagnostic Clinical Trials on Human Blood
Online Disruptive Technologies, Inc. (OTC PINK: ONDR) (the "Company") is pleased to announce that its majority owned Israeli subsidiary, Savicell Diagnostic Ltd

Epigenetics Market Worth $16.31 Billion by 2022: Grand View Research, Inc.
The global epigenetics market is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.

NCCN Collaborates With Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer
FORT WASHINGTON, PA--(Marketwired - November 30, 2015) - New molecules and pathways with pivotal functions in regulating the immune system have been discovered recently, providing new understanding of how tumor cells avoid the immune system

ALCF Launches Billboard Campaign to #BeatLungCancer
SAN CARLOS, CA--(Marketwired - November 19, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) launched a thought-provoking billboard campaign in Southern California this month to address the stigma surrounding lung cancer patients. The billboards feature 31-year-old Stage IV lung cancer survivor Emily Bennett Taylor and 32-year-old Stage IV lung cancer survivor Sandy Jauregui.

Medtronic Sponsors the Addario Lung Cancer Foundation's "Simply the Best" Dinner and Gala
SAN CARLOS, CA--(Marketwired - November 12, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) today announced Medtronic as a title sponsor for its tenth annual "Simply the Best" Dinner and Gala. Through the sponsorship, Medtronic is demonstrating its commitment to reduce lung cancer morbidity by improving early diagnosis, thereby leading to earlier, personalized treatment

Bristol-Myers Squibb Sponsors the Addario Lung Cancer Foundation's "Simply the Best" Dinner and Gala
SAN CARLOS, CA--(Marketwired - November 10, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) today announced Bristol-Myers Squibb (BMS) as a title sponsor for its tenth annual "Simply the Best" Dinner and Gala

BioCancell Advances Intellectual Property Portfolio in the United States
BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer-related diseases, today announced that the U.S. Patent and Trademark Office has approved a patent for BioCancell's second-generation drug, BC-821

Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab
Business Wire IndiaMerck and Pfizer announced the opening of trial sites for an international Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
Business Wire IndiaBoehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for its novel, 3rd-generation, epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI), BI 1482694* (HM61713**)

Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Business Wire IndiaBoehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore, 18-21 December 2015

Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Business Wire IndiaMerck and Pfizer announced the initiation of two Phase III studies of avelumab*, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates

Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Business Wire IndiaInsights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lung cancer (NSCLC), in being tested for EGFR mutations, leaving some without access to the most appropriate treatment for them.

Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI® (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Business Wire IndiaPfizer Inc

Merck and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Business Wire IndiaMerck and Pfizer announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen

Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs
Business Wire IndiaBoehringer Ingelheim is launching a new research and development (R&D) strategy and a five-year R&D investment programme. This new plan was announced at its R&D press conference in Berlin. The company pledges to invest a total of 11 billion euros in its new R&D programme over the next five years

Takeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting
Business Wire IndiaTakeda Pharmaceutical Company Limited (TSE: 4502) announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015

Helix Announces Initiation of First Clinical Site for US Study
Helix BioPharma (TSX: HBP) (FRANKFURT: HBP) announced today that its United States Phase I study of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous non-small cell lung cancer ("LDOS001") has been initiated at The University of Texas MD Anderson Cancer Center in Houston, Texas

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Zenosense, Inc

Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer
Peregrine Pharmaceuticals, Inc

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc

Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity
Avid Bioservices, Inc, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced it has initiated an expansion of its biomanufacturing capacity. Avid provides high quality clinical and commercial manufacturing services under cGMP for the biotechnology and biopharmaceutical industries

IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.

Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Zenosense, Inc

Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014
Peregrine Pharmaceuticals, Inc

Fort Lauderdale Law Firm Wins $4 Million Verdict Against 3 Cigarette Companies
FORT LAUDERDALE, FL--(Marketwired - November 25, 2014) - A South Florida jury found three tobacco companies partially responsible for the lung cancer of a smoker and awarded more than $4 million to the man's estate.

Improved Outcomes in Non-Small Cell Lung Cancer Due to Advancements in Screening, Diagnosis, Radiology, and Systemic Therapies
FORT WASHINGTON, PA--(Marketwired - November 19, 2014) - The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC), one of the eight original NCCN Guidelines® published in November 1996.

Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a

Printed NCCN Guidelines for Patients(R) Now Available Through Amazon.com
FORT WASHINGTON, PA--(Marketwired - November 10, 2014) - The National Comprehensive Cancer Network® (NCCN®), with the support of the NCCN Foundation®, announces the availability of printed versions of the NCCN Guidelines for Patients® for order on Amazon

Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the Society for Immunotherapy of Cancer's (SITC) 29th Annual Meeting and Associated Programs

Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the first of four presentations of clinical and preclinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab

Indi(R) Secures Contracts for Xpresys(R) Lung With Multiplan and Five Other PPOs; Blood Test for Pulmonary Nodules Now Available to 200 Million Covered Lives
Indi® (Integrated Diagnostics), an emerging leader in molecular diagnostics, today announced that the company has secured contractual agreements with MultiPlan and five other PPOs (preferred provider organizations) for Xpresys® Lung, the first non-invasive molecular blood test for the assessment of pulmonary nodules

Takeda Announces Formalization of Takeda Oncology to Enhance Discovery, Development and Global Commercialization of Breakthrough Cancer Medicines
Takeda Pharmaceutical Company Limited (TSE:4502) has announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide

Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy
For media outside UK, US and Canada only

Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology
Merck (MRK GY) (FWB:MRK) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
While it may not be surprising that breast and lung cancers are top of mind when people hear the word “cancer,” 60% of respondents to a recent six-country survey about cancer awareness know almost nothing about pancreatic cancer, a leading cancer killer

New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy
For Media In Asian Countries Only For Whom The Data Is Relevant (For media outside UK, US and Canada only)

Heat Biologics Announces Its Phase 1/2 Study of HS-410 in Bladder Cancer Is Open for Enrollment
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that its Phase 1/2 Study of HS-410 in bladder cancer patients is open for enrollment. HS-410 is a biologic product candidate designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer.

Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States

University of California San Diego and John Muir Medical Center Initiated Treating Patients for Colon and Lung Cancer Utilizing IsoRay's Cesium-131 Seeded Mesh
IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has two new medical centers using its sutured seeds in mesh to treat colon and lung cancers.

NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute(TM) Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer

Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the appointment of Anil K. Goyal, Ph.D. as Vice President of Business Development. Dr

Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan
Ohr Pharmaceutical (NASDAQ: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced that full results from a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia were presented yesterday at the 7th International Cachexia Conference in Kobe, Japan

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter of fiscal year (FY) 2014 ended October 31, 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology
Rosetta Genomics Ltd

NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a first in human Phase 1 clinical trial of NLG919. This is NewLink's second IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor that will initially be tested in patients with recurrent advanced solid tumors

Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test(TM)
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced that the New York State Department of Health ("NYSDOH") has given the Company conditional approval for the Rosetta Kidney Cancer Test™ for testing on patient samples from the State. New York is the only U.S

Rosetta Genomics Issues Letter to Shareholders
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.rosettagenomics.com.

Sunshine Biopharma to Re-Domicile in Canada for Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations

Heat Biologics, Inc. to Present at 25th Annual Piper Jaffray Healthcare Conference
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a company overview at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 1:10 p.m. Eastern at the New York Palace Hotel in New York City.

Rosetta Genomics to Participate in the LD Micro Conference
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the LD Micro Conference being held December 3-5, 2013 at the Luxe Sunset Bel Air Hotel in Los Angeles.

NCCN Publishes New Patient Resource for Stage 0 Breast Cancer
FORT WASHINGTON, PA--(Marketwired - November 25, 2013) - The National Comprehensive Cancer Network® (NCCN®), with the support of the NCCN Foundation®, announces the availability of NCCN Guidelines for Patients®: Stage 0 Breast Cancer -- the latest addition to the library of NCCN Guidelines for Patients® available free-of-charge at NCCN.org/patients

Heat Biologics Successfully Completes Manufacturing of HS-410 to Start Phase 1/2 Bladder Cancer Trial
Heat Biologics, Inc

Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
Novartis International AG /Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

LA County Urges LGBT Community to 'Break Up With Tobacco' in New Anti-Smoking Campaign
The Los Angeles County Department of Public Health today launched an unprecedented new anti-smoking campaign aimed at the lesbian, gay, bisexual and transgender (LGBT) community. The lesbian, gay and bisexual (LGB) populations in California smoke at more than twice the rate of the heterosexual population.

'Twas the Night Before Christmas Released in Chinese for the First Time in 189 Years by Awarding Winning Anti-Tobacco Activist
The tobacco epidemic and China according to recent studies:

Overcame Cancer to Celebrate 100th Birthday, Accessibility to Technology and Expertise at HCG, Helps Appaswamy in the Journey
Mr. Appaswamy, Lung Cancer Survivor, seeks a second opinion from Health Care Global (HCG), The Specialist in Cancer Care, overcomes cancer, celebrated his 100th birthday after being treated for cancer. The patient sought a second opinion after being diagnosed with lung cancer. About Mr. Appaswamy: Mr. Appaswamy, was born in Tanjavur District, Tamil Nadu, on April 12th, 1913

Clinical Update: Helix BioPharma Corp. Completes Enrollment in First Cohort and Initiates Second Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announced the opening of patient screening for the second dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland

Equity Brief: Ratings Changes for December 20th: SASR, SD, SGY, SLGN, SNSS, ST, STN, TAP
A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Viratech Announces Acquisition of Cancer.im for $6.2 Million in Securities
Viratech Corp. (PINKSHEETS: VIRA) http://viratech.org, the first open source biotech research social network platform, announced today an acquisition merger with Cancer.im, Inc., in exchange for $6.2 million in Viratech restricted common stock.

Market for Kinase Inhibitors Heats Up: Kalorama
The cancer kinase inhibitor market is estimated at $12.1 billion worldwide for 2012, representing annual revenue growth of 16.9% over 2007. The effectiveness of kinase inhibitors has sparked interest from major pharmaceutical companies, according to the healthcare market research publisher, Kalorama Information

Near Term Catalyst Has ArQule Poised for a Move Up
ArQule, Inc. engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.

ArQule (ARQL) Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow

A Strong Speculative BioPharma Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found to Be Effective Against Multidrug Resistant Uterine Cancer Cells
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate, was found to be effective at killing Multidrug Resistant Uterine Cancer Cells in vitro

Helix BioPharma Corp. Announces Sale of Rivex Pharma Division to Pharmascience Inc.
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive agreement for the sale of its Rivex Pharma division to Pharmascience Inc. ("Pharmascience") for gross cash proceeds of up to $8.5 million (the "Rivex Transaction")

Sunshine Biopharma Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed six IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate

Laughlin Constable and Wisconsin Department of Tourism to Bring Widen Digital Asset Management Into Their Communications Workflows
Widen Enterprises, a Madison-based provider of digital asset management solutions (Widen Media Collective), has been chosen by Laughlin Constable to meet the agency's DAM software needs in serving the Wisconsin Department of Tourism.

Cambridge Heart Reports Results for the Three and Nine Months Ended September 30, 2012
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported results for the three and nine months ended September 30, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on November 14, 2012.

IsoRay, Inc. Reports First Quarter Results
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gyn cancer announced its financial results for the quarter ended September 30, 2012.

Picomole Granted U.S. Patent for its Breath Analysis Technology
Picomole Instruments Inc., the world leader in infrared technologies for breath analysis, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,288,727 entitled "Apparatus and method for rapid and accurate quantification of an unknown, complex mix".

Sunshine Biopharma Initiates IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate

Scientists and Clinicians Collaborate on 8 Projects to Better Understand and Treat Diseases Prevalent in Asia
Singapore announces 8 biomedical sciences research programmes to advance understanding and treatment of diseases especially prevalent amongst the Asian population. These programmes will see biomedical scientists and clinicians working collaboratively to bring about greater healthcare benefits to society and create economic growth for Singapore

Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
Novartis International AG /Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Holzer Holzer & Fistel, LLC Has Filed a Class Action Lawsuit on Behalf of Investors in Peregrine Pharmaceuticals, Inc.; Reminds Investors With Large Losses of November 27th Lead Plaintiff Deadline
Holzer Holzer & Fistel, LLC has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of purchasers of Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NASDAQ: PPHM) common stock who purchased shares between August 30, 2012 and September 26, 2012, inclusive (the "Class Period")

ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study

Beach Boys reuniting to mark golden anniversary in 2012
The surviving members of band 'The Beach Boys' are planning to reunite in 2012 to celebrate their golden anniversary year, commemorating their first important record deal with the Capitol label.

Peregrine Provides Update on HCV Clinical Program
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV)

Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer
STOCKHOLM, SWEDEN - December 28, 2011. Axelar AB, a Karolinska Development AB portfolio company, today announces that the first patient has been dosed in a randomized Phase II study on non-small cell lung cancer (NSCLC) patients of its drug candidate AXL1717

Verisante Starts FDA Approval Process and Provides Operational Update
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF)(PINKSHEETS: VRSEF)(FRANKFURT: V3T) (the "Company" or "Verisante"), a leader in skin cancer detection technology, has begun the process to obtain US Food and Drug Administration (FDA) approval for Verisante Aura

Rosetta Genomics Sells Ownership in Rosetta Green
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held. Prior to the transaction, Rosetta Genomics owned approximately 50

Caltech and Integrated Diagnostics Researchers Receive Grand Challenges Point-of-Care Diagnostics Grant

Soon, biosensors to detect lung cancer from exhaled breath
Scientists are developing biosensors capable of detecting the presence of tumour markers of lung cancer in exhaled breath.

Soybean compounds enhances effects of cancer radiotherapy
Compounds found in soybean compounds make radiation therapy to treat lung cancer tumours more effective, a new study has revealed.

Radiation therapy to become more effective and safer
Radiation therapy may soon have fewer side effects and doubled efficiency, a new study has revealed.

Now, breath test can detect, characterize lung cancer
A new breath test will now help in identifying and differentiating between the types of lung cancer in humans with high accuracy, a new study has suggested.

Comment on this story

Share